שימוש בחלבון TAT-1 מוירוס HIV להגברת חדירות מחסום הדם-מוח לאפשר החדרת תרופות אל גידולי מוח

Enhanced blood-brain barrier penetration of high and low molecular weight therapeutic agents, following intratumoral delivery of a peptide derived from HIV-1 Tat protein: A combined approach for the treatment of brain tumors

Contact Person:

Dr. Itzik Cooper

PI:

Dr. Itzik Cooper, Dr. Yael Mardor

Funding:

A collaborative research proposal WIS-Sheba in Biomedical research-2012-2013, $100K

 Approving Institute:

Sheba/Weizmann

Research Description:

Developing new compounds derived from the HIV-TAT protein that will act as blood-brain barrier openers to allow the entrance of impermeable drugs to the brain. In-vitro and in-vivo study.

JSNC personnel who take part in the research:

Dr. Itzik Cooper

Collaborations - local and global:

Dr. Yael Mardor (Sheba)

Prof. Yoram Shechter (Weizmann)

Prof. Mati Fridkin (Weizmann)

List of Published Results:

1. Cooper I, Sasson K, Teichberg VI, Schnaider-Beeri M, Fridkin M, Shechter Y. Peptide derived from HIV-1 TAT protein destabilizes a monolayer of endothelial cells in an in vitro model of the blood-brain barrier and allows permeation of high molecular weight proteins. J Biol Chem. 2012 Dec 28;287(53):44676-83. PubMed PMID: 23150670.